- Tesamorelin is an FDA-approved prescription biologic for one narrow indication: reduction of excess visceral abdominal fat in adults living with HIV who have lipodystrophy. The European marketing authorisation application was withdrawn by the applicant in 2012 and the product has no EU authorisation.
- The current prescribing information lists arthralgia, injection site erythema, injection site pruritus, pain in extremity, peripheral edema and myalgia as the adverse reactions reported in more than 5% of treated patients.
- Injection site reactions were the single largest difference against placebo in the pooled 26-week phase 3 data, reported in 17% of tesamorelin recipients versus 6% of placebo recipients.
- Tesamorelin raises IGF-1 by design, because it stimulates endogenous growth hormone release. The label instructs prescribers to monitor IGF-1 and to consider stopping treatment when elevations persist, and the European regulator cited unresolved concerns about long-term IGF-1 elevation.
- The label requires glucose evaluation before and during therapy and warns that glucose intolerance or diabetes may develop, while the pooled phase 3 analysis found no clinically meaningful group differences in glucose parameters at weeks 26 and 52.
- The label contraindicates use in pregnancy, in active malignancy, in disruption of the hypothalamic-pituitary axis and in known hypersensitivity to the product or its excipients.
- Essentially all of the published safety data come from adults living with HIV who had lipodystrophy. Safety outside that population has not been established, and this article is educational only, not medical advice.
What is tesamorelin approved for, and in whom was it studied?
Any honest discussion of tesamorelin side effects has to begin with the population in which they were measured. Tesamorelin is a synthetic analogue of human growth hormone-releasing hormone, GHRH(1-44), modified at its N-terminus with a trans-3-hexenoyl group that slows enzymatic degradation. It does not supply growth hormone. It stimulates the pituitary to release the patient's own growth hormone, which in turn raises insulin-like growth factor 1 (IGF-1). Nearly every adverse reaction described below follows from that single mechanism.
In the United States, tesamorelin is a prescription biologic. The FDA-approved indication is narrow: reduction of excess visceral abdominal fat in adults living with HIV who have lipodystrophy. It has been marketed under the names Egrifta, Egrifta SV and, since the FDA approved the F8 formulation on 25 March 2025, Egrifta WR. The approval is not an obesity indication, not an anti-aging indication and not a body composition indication for the general population.
In Europe the picture is different. Ferrer Internacional notified the Committee for Medicinal Products for Human Use on 21 June 2012 that it was withdrawing its marketing authorisation application for Egrifta. The company's withdrawal letter stated that the CHMP considered that the data provided did not allow it to conclude on a positive benefit-risk balance. Among the reasons the agency published were the practical difficulty of distinguishing excess abdominal fat caused by lipodystrophy from excess fat caused by obesity, and a major safety concern that high levels of IGF-1 may be associated with an increased risk of cancer and a potential worsening of diabetic eye disease. Tesamorelin therefore has no European marketing authorisation.
The safety database rests on two multicentre, double-blind, placebo-controlled phase 3 trials and their 26-week extensions, conducted in antiretroviral-treated adults with HIV and excess abdominal fat. The first, published by Falutz and colleagues in the New England Journal of Medicine in 2007, randomised 412 patients; visceral adipose tissue measured by CT fell by 15.2% with tesamorelin and rose by 5.0% with placebo over 26 weeks. The second, reported in 2010, randomised 404 patients and found a 10.9% reduction in visceral adipose tissue versus 0.6% with placebo. A pooled analysis of 806 patients (543 on tesamorelin, 263 on placebo) forms the backbone of the adverse reaction tables in the label. For a broader overview of the molecule itself, see our tesamorelin guide.
This article is for educational purposes only. It describes what published sources report. It is not medical advice, and nothing here should be used to start, change or stop any treatment. Those decisions belong to a qualified healthcare professional.
Which side effects were most frequent in the pivotal trials?
The Highlights section of the current prescribing information names the reactions reported in more than 5% of treated patients: arthralgia, injection site erythema, injection site pruritus, pain in extremity, peripheral edema and myalgia. That list is short, and it is also revealing. Five of the six items are either a local reaction at the injection site or a musculoskeletal and fluid-related complaint, which is exactly the adverse reaction profile expected from a compound that increases growth hormone secretion.
The pooled 26-week data from the two phase 3 trials, as reproduced in the prescribing information, compare 543 tesamorelin recipients with 263 placebo recipients. The table below gives the reactions reported in at least 1% of patients and more frequently with tesamorelin than with placebo.
| Adverse reaction | Tesamorelin (n=543) | Placebo (n=263) |
|---|---|---|
| Injection site reaction | 17% | 6% |
| Arthralgia (joint pain) | 13% | 11% |
| Pain in extremity | 6% | 5% |
| Myalgia (muscle pain) | 6% | 2% |
| Peripheral edema | 6% | 2% |
| Paresthesia (tingling, numbness) | 5% | 2% |
| Rash | 4% | 2% |
| Vomiting | 3% | 0% |
| Pruritus (itching) | 2% | 1% |
Two observations matter when reading this table. First, the placebo column is not empty. Joint pain was reported by 11% of patients who received no active product at all, which is a reminder that in a population living with HIV and taking antiretroviral therapy, many symptoms have causes unrelated to the injected compound. The attributable excess for arthralgia in these pooled data is small. Second, the clearest signals are local reactions, muscle pain, peripheral edema and paresthesia, where the rate with tesamorelin was roughly two to three times the placebo rate.
The 26-week extension phase, published by Falutz and colleagues in AIDS in 2008, followed patients to 52 weeks. The authors reported that tesamorelin was generally well tolerated during the extension and that adverse event rates were comparable to those of the first phase, with no clinically significant glucose changes over the full 52 weeks. They also reported that visceral fat remained roughly 18% below baseline at 52 weeks and that it re-accumulated once the product was stopped, which is a pharmacological observation rather than a safety finding, but one that shapes how clinicians weigh the risk-benefit balance over time.
How often do injection site reactions occur, and what do they look like?
Injection site reactions are the most common and most consistently reported category of tesamorelin side effects. In the pooled 26-week phase 3 data, 17% of tesamorelin recipients reported an injection site reaction compared with 6% of placebo recipients. Because placebo injections were also given subcutaneously, that 6% baseline is informative: part of the local reaction burden comes from the act of daily subcutaneous injection itself, and part from the compound.
The label describes these reactions in terms of erythema (redness), pruritus (itching), pain, irritation and bruising at the site. The Highlights section specifically singles out injection site erythema and injection site pruritus as exceeding the 5% threshold. These are local, visible and usually self-limiting events rather than systemic ones.
Local reactions also appear in later, smaller trials. In the randomised trial of tesamorelin in people with HIV and non-alcoholic fatty liver disease published in The Lancet HIV in 2019, Stanley and colleagues randomised 61 participants and reported that injection site complaints were more frequent in the tesamorelin group than the placebo group, but that none of them were judged serious.
One caveat worth stating plainly: the magnitude of local reactions reported in clinical trials reflects a pharmaceutical-grade product, prepared and administered under trial conditions with trained supervision. The literature cannot be read as describing what happens with unregulated material of uncertain purity or sterility, where contamination and endotoxin are additional and uncharacterised sources of local reaction. We discuss that general problem in our article on peptide safety.
Finally, the label distinguishes ordinary injection site reactions from genuine hypersensitivity. A reaction that spreads beyond the site, or that involves hives, flushing or systemic symptoms, is treated in the label as a hypersensitivity event and is discussed separately below.
Why does tesamorelin cause joint pain, swelling and carpal tunnel symptoms?
Growth hormone promotes sodium and water retention. The prescribing information states this directly in its fluid retention warning: the effect manifests as increased tissue turgor and musculoskeletal discomfort, resulting in adverse reactions such as edema, arthralgia and carpal tunnel syndrome. Critically, the label adds that these reactions are either transient or resolve with discontinuation of treatment. That single sentence explains why so much of the adverse reaction list is musculoskeletal, and it also explains why most of it is reversible.
The numbers in the pooled phase 3 data fit the mechanism. Peripheral edema was reported in 6% of tesamorelin recipients versus 2% on placebo. Myalgia was also 6% versus 2%. Paresthesia, the tingling or numbness that often accompanies soft tissue swelling compressing a nerve, was 5% versus 2%. Pain in extremity was 6% versus 5%. Carpal tunnel syndrome is the clinically important end of this spectrum, because median nerve compression at the wrist can produce persistent hand numbness and weakness if it is not recognised.
Fluid retention is also the reason that tesamorelin's adverse reaction profile resembles that of recombinant growth hormone rather than that of a typical small-molecule drug. The practical difference, and part of the original rationale for a GHRH analogue, is that stimulating the pituitary preserves the physiological pulsatile pattern of growth hormone release and remains subject to negative feedback, which theoretically limits the degree of exposure compared with direct administration of growth hormone. That is a pharmacological argument, not a demonstrated safety advantage, and the regulatory record does not treat it as one. Readers comparing GHRH analogues with other growth hormone secretagogues may find our scientific comparison of HGH-related peptides useful for context.
The label also carries a separate warning class inherited from growth hormone pharmacology: increased mortality in patients with acute critical illness, with the instruction to consider discontinuation in critically ill patients. This does not describe outpatient use, but it is part of the documented risk framework and belongs in any complete account of the product's safety section.
What does the label say about IGF-1 elevation?
IGF-1 elevation is not a side effect in the ordinary sense. It is the intended biochemical consequence of stimulating growth hormone release, and it is the single safety parameter that regulators have scrutinised most closely.
The prescribing information is explicit that the product increases IGF-1 and instructs prescribers to monitor IGF-1 levels during therapy. It further states that discontinuation should be considered in patients with persistent elevations of IGF-1, giving a standard deviation score above 3 as the example threshold, particularly if the efficacy response is not robust. In other words, the label frames continued treatment as conditional on both the biochemical response and the clinical benefit.
The scale of the effect was quantified in the original clinical program. The label for the original formulation reports that among patients treated for 26 weeks, 47% had IGF-1 levels above 2 standard deviation scores and 36% above 3 standard deviation scores, with the effect visible as early as 13 weeks. The label for the 2 mg formulation reports that at the end of a 52-week treatment period, 34% had an IGF-1 score above 2 and 23% above 3. The label then states plainly that the effects of prolonged elevations in IGF-1 levels are unknown.
That uncertainty is precisely what the European regulator refused to set aside. In the published questions and answers on the withdrawal of the Egrifta application, the CHMP's major safety concern was summarised as the observation that high levels of IGF-1 may be associated with an increased risk of cancer and a potential worsening of diabetic eye disease. The FDA label addresses the same two issues through monitoring and contraindication rather than refusal: it contraindicates active malignancy, states that any pre-existing malignancy should be inactive and its treatment complete before starting, and instructs that patients with diabetes be monitored at regular intervals for the development or worsening of retinopathy.
No published trial of tesamorelin has been designed or powered to detect a change in cancer incidence. The 26-week and 52-week horizons of the pivotal program are far too short for that question. The correct summary of the evidence is that IGF-1 rises substantially in a large minority of treated patients, that the long-term consequences of this elevation have not been characterised, and that both regulators treated it as the central open question.
How does tesamorelin affect blood sugar and diabetes risk?
Growth hormone opposes the action of insulin, so any compound that increases growth hormone secretion raises a legitimate question about glucose metabolism. The label treats this as a warning rather than a contraindication: it states that glucose intolerance or diabetes mellitus may develop with use, and instructs prescribers to evaluate glucose prior to and during therapy.
The trial evidence is more reassuring than the warning alone might suggest, within the limits of what was studied. The pooled analysis of the two phase 3 trials, published by Falutz and colleagues in the Journal of Clinical Endocrinology and Metabolism in 2010, concluded that tesamorelin was overall well tolerated with no clinically meaningful differences between groups in glucose parameters at weeks 26 and 52. The 52-week extension report in AIDS reached the same conclusion, describing glucose changes over 52 weeks as not clinically significant. The 2010 report of the second pivotal trial likewise described the body composition changes as occurring without disturbance of glucose.
A dedicated safety study extends this to people who already have diabetes. Clemmons, Miller and Mamputu published a 12-week randomised, placebo-controlled trial in 53 patients with type 2 diabetes in PLoS One in 2017. At week 12 the authors found that tesamorelin did not alter insulin response or glycemic control, and they reported that no patient discontinued because of loss of diabetes control. That trial was short, small and conducted in people whose diabetes was stable, so it answers a narrow question rather than a general one.
Two limits deserve emphasis. First, mean values across a trial population can conceal movement in individuals. Regulatory review of the pivotal studies noted a shift of some patients from the pre-diabetic range into the diabetic range during treatment, which is consistent with the label's decision to require glucose monitoring rather than simply declare the issue settled. Second, no trial has followed glucose metabolism on tesamorelin for several years. A 52-week horizon is not a long-term answer about insulin sensitivity.
For patients who already have diabetes, the label adds the retinopathy instruction described above, because IGF-1 is implicated in retinal neovascularisation. That monitoring requirement is specific to diabetic patients and is stated separately from the general glucose warning.
What is known about allergic reactions and antibody formation?
Tesamorelin is a 44-amino-acid peptide with a synthetic acyl modification, and like other peptide biologics it provokes an immune response in a substantial share of recipients. The label states that hypersensitivity reactions occurred in 4% of patients treated in clinical trials, and lists the manifestations as pruritus, erythema, flushing, urticaria and rash. The label instructs that patients with suspected hypersensitivity seek immediate medical attention and that treatment be discontinued.
The immunogenicity data are more striking than the hypersensitivity rate. In the clinical trials conducted with the original 1 mg formulation, the label reports that anti-tesamorelin IgG antibodies were detected in 50% of patients treated for 26 weeks and 47% of those treated for 52 weeks. Among the subset of patients who experienced hypersensitivity reactions, anti-tesamorelin IgG antibodies were detected in 85%, which suggests a relationship between antibody formation and clinical hypersensitivity even though most antibody-positive patients had no reaction at all.
The label also reports in vitro neutralising antibodies at week 52: in 10% of treated patients against tesamorelin itself and in 5% against native human GHRH. Cross-reactivity against an endogenous hormone is the kind of finding that would normally require long-term follow-up to interpret, and no such follow-up has been published. The Canadian regulatory summary of the product reached a similar characterisation, noting that about half of patients developed antibodies, that this predisposed to hypersensitivity reactions, and that it did not appear to adversely affect efficacy.
Immunogenicity rates are also assay-dependent and formulation-dependent, so figures from the original formulation should not be assumed to apply unchanged to the current extended-release product. Pharmacokinetic bioequivalence between formulations has been demonstrated, but bioequivalence is not an immunogenicity equivalence claim.
Who does the label say must not receive tesamorelin?
Contraindications are the strongest statements a label makes, and the tesamorelin label lists four. They are reported here as the label states them, not as clinical guidance.
- Disruption of the hypothalamic-pituitary axis due to hypophysectomy, hypopituitarism, pituitary tumor or pituitary surgery, head irradiation or head trauma. The logic is mechanistic: a GHRH analogue acts on the pituitary, so it cannot work as intended when that axis is damaged, and stimulation in the presence of a pituitary lesion is not acceptable.
- Active malignancy. The label states that the product induces the release of endogenous growth hormone, a known growth factor, and that patients with active malignancy must not be treated. The warnings section adds that any pre-existing malignancy should be inactive and its treatment complete before initiation.
- Pregnancy. The label states that the product is contraindicated in pregnant women because modifying visceral adipose tissue offers no benefit in pregnancy and could result in fetal harm.
- Known hypersensitivity to tesamorelin or to any of the excipients in the product.
Alongside the contraindications, the label defines the situations that require active surveillance during therapy: IGF-1 levels, glucose before and during treatment, retinopathy in diabetic patients, fluid retention and musculoskeletal symptoms, injection site reactions, and signs of hypersensitivity. It also instructs that discontinuation be considered in patients who become critically ill.
One structural point is easy to miss. The label's monitoring framework presumes laboratory access and prescriber oversight. IGF-1 standard deviation scores, glucose panels and retinal examinations are not self-assessments. The safety profile documented in the trials is inseparable from the clinical supervision under which it was generated, and that supervision is itself part of how the risk was contained.
If you have been prescribed tesamorelin, or are considering whether it is relevant to you, discuss it with the prescribing clinician. Do not use this article as a basis for starting, adjusting or interrupting any therapy.
What is not known about tesamorelin outside its approved indication?
The honest answer is: almost everything. The entire published safety record for tesamorelin comes from adults living with HIV who had lipodystrophy and excess visceral abdominal fat, plus small trials in related clinical populations such as HIV-associated fatty liver disease and stable type 2 diabetes. Interest in tesamorelin has grown well beyond that indication, and that interest is not supported by data.
Consider what the pivotal program does not tell you. It does not tell you how tesamorelin behaves in people without HIV or without lipodystrophy, because none were enrolled. It does not tell you how adverse reaction rates change beyond 52 weeks, because the trials ended. It does not tell you whether sustained IGF-1 elevation translates into any clinical harm, because no trial was powered to detect it and the label itself says the effects of prolonged elevation are unknown. It does not tell you anything about use in people who do not need visceral fat reduction, where the benefit side of the balance is absent by definition and only the risks remain.
There is also a regulatory reality that is easy to overlook. Tesamorelin is a prescription biologic in the United States and has no European marketing authorisation. Material sold outside the pharmaceutical channel is not the product studied in these trials and carries no guarantee of identity, purity, sterility or stability. None of the safety figures quoted in this article can be transferred to such material. Our overview of peptide safety in general covers the quality questions that apply, and the tesamorelin tools page addresses practical handling questions separately from safety.
A balanced reading of the evidence is therefore specific rather than global. In the population studied, over the durations studied, under clinical supervision, tesamorelin was reported as generally well tolerated, with a reaction profile dominated by local injection site effects and reversible fluid-related musculoskeletal complaints, plus a biochemical IGF-1 elevation whose long-term meaning remains unresolved and which one major regulator considered a reason not to authorise the product. Extending that sentence to any other population is not supported by evidence.
Medical disclaimer: this content is educational and does not constitute medical advice, diagnosis or a recommendation of any kind. Tesamorelin is a prescription product in the jurisdictions where it is approved, and its legal status varies by country. Consult a qualified healthcare professional for any question about your own health or treatment.
Frequently Asked Questions
What are the most common tesamorelin side effects according to the label?
Is tesamorelin approved by the FDA and the EMA?
Why does tesamorelin raise IGF-1, and is that a problem?
Can tesamorelin cause diabetes or raise blood sugar?
Do injection site reactions to tesamorelin go away?
Why does tesamorelin cause joint pain and carpal tunnel symptoms?
Who should not take tesamorelin according to the prescribing information?
Are tesamorelin safety data applicable to people who do not have HIV?
Recommended products
Research peptides selected for quality and purity:
GHK-Cu
Anti-Aging Compound
GHK-Cu Pen
Pre-filled Pen GHK-Cu
GLOW-UP Ritual
3-pen pack: Glow, NAD+, GHK-Cu
Test your knowledge
Quick quiz · 6 questions
Sources
- Theratechnologies Inc. (2026). EGRIFTA WR (tesamorelin for injection) prescribing information: indications, contraindications, warnings and precautions, adverse reactions, immunogenicity. DailyMed, U.S. National Library of Medicine. (dailymed.nlm.nih.gov)
- European Medicines Agency, Committee for Medicinal Products for Human Use (2012). Ferrer Internacional, S.A. withdraws its marketing authorisation application for Egrifta (tesamorelin). EMA press release and questions and answers document. (ema.europa.eu)
- Falutz J, Allas S, Blot K, et al. (2007). Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine (PMID 18057338). (PubMed)
- Falutz J, et al. (2008). Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS (PMID 18690162). (PubMed)
- Falutz J, Mamputu JC, Potvin D, et al. (2010). Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. Journal of Clinical Endocrinology and Metabolism (PMID 20554713). (PubMed)
- Falutz J, Potvin D, Mamputu JC, et al. (2010). Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. Journal of Acquired Immune Deficiency Syndromes (PMID 20101189). (PubMed)
- Stanley TL, Fourman LT, Feldpausch MN, et al. (2019). Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. The Lancet HIV (PMID 31611038). (PubMed)
- Clemmons DR, Miller S, Mamputu JC (2017). Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: a randomized, placebo-controlled trial. PLoS One (PMID 28617838). (PMC)